Table 1.
CART approaches for T-cell malignancies
| Target antigen | Expression in malignant T cells, %∗ | Expression in healthy T cells, % | Predicted level of healthy T-cell depletion (%) | Notes | Representative reference |
|---|---|---|---|---|---|
| CD3 | ∼100 | 100 | Pan-depleting (100) | Pan–T-cell depleting fratricide as an issue; as a bridge to HSCT only | Chen et al40 |
| CD5 | ∼100 | 100 | Pan-depleting (100) | Pan–T-cell depleting fratricide as an issue; as a bridge to HSCT only | Mamonkin et al18 |
| CD7 | ∼100 | 100 | Pan-depleting (100) | Pan–T-cell depleting fratricide as an issue; as a bridge to HSCT only | Gomes-Silva et al19 |
| CD4 | Only in CD4+ T-ALL | 65 | Partial depletion (65) | Utility in CD4+ PTCLs only, elimination of all CD4+ cells; preservation of CD8+ T cells | Pinz et al14 |
| CCR4 | ∼50 | 50 | Partial depletion (50) | Incomplete cancer cell killing; partial depletion of healthy T cells | Perera et al16 |
| CD30 | 100 in the anaplastic large-cell lymphoma subtype; lower in other subtypes |
Expression in various leukocyte subsets | Partial depletion; eosinopenia noted in trial | Expressed in activated B and T cells and natural killer cells; low levels in activated monocytes and eosinophils; activity largely limited to anaplastic large-cell lymphoma subtype (∼13%) | Ramos et al15 |
| TRBC1 | 100 in ∼50 of cases; 0 in the other half | 50 | Partial depletion (50) | Utility in only ∼50% of PTCL cases; depletion of ∼50% of healthy T cells | Maciocia et al31 |
| T- cell receptor vβ family | ∼100 | ∼3-5 | Minimal depletion (∼3-5) | Minimal impact on healthy T cells; only limited fratricide; not an issue; no need for HSCT | This report |
HCST, hematopoietic stem cell transplant; T-ALL, T-cell acute lymphoblastic leukemia; TCR, T-cell receptor; TRBC1; TCRβ chain 1.
∗
Represents expression in T-cell lymphomas bearing αβ TCRs (does not include less prevalent γδ or natural killer subtypes).